The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant
Adagio...
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing...
Photo by Chris Montgomery on Unsplash
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of...
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
Bicycle Therapeutics plc (...
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday.
NRx's stock opened Thursday...
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19...
